Lateralized Hippocampal Effects of Vasoactive Intestinal Peptide on Learning and Memory in Rats in a Model of Depression

Overview

Journal Psychopharmacology (Berl)

Specialty Pharmacology

Date 2011 Dec 14

PMID 22160165

Citations 4

Authors

Margarita Ivanova

Stiliana Belcheva

Iren Belcheva

Negrin Negrev

Roman Tashev

Affiliations

Soon will be listed here.

Abstract

Rationale: Findings of pharmacological studies revealed that vasoactive intestinal peptide (VIP) plays a modulatory role in learning and memory. A role of the peptide in the neurobiological mechanisms of affective disorders was also suggested.

Objective: The objectives are to study the involvement of VIP in learning and memory processes after unilateral and bilateral local application into hippocampal CA1 area in rats with a model of depression (bilateral olfactory bulbectomy--OBX) and to test whether VIP receptors could affect cognition.

Results: VIP (50 ng) and combination (VIP(6-28) 10 ng + VIP 50 ng) microinjected bilaterally or into the right CA1 area improved the learning and memory of OBX rats in shuttle-box and step-through behavioral tests as compared to the saline-treated OBX controls. Left-side VIP microinjections did not affect the number of avoidances (shuttle box) and learning criteria (step through) as compared to the left-side saline-treated OBX controls. The administration of the combination into left CA1 influenced positively the performance in the step-through task. VIP antagonist (VIP(6-28), 10 ng) did not affect learning and memory of OBX rats. These findings suggest asymmetric effect of VIP on cognitive processes in hippocampus of rats with OBX model of depression.

Conclusion: Our results point to a lateralized modulatory effect of VIP injected in the hippocampal CA1 area on the avoidance deficits in OBX rats. The right CA1 area was predominantly involved in the positive effect of VIP on learning and memory. A possible role of the PAC1 receptors is suggested.

Citing Articles

Spatial Distribution of Inhibitory Innervations of Excitatory Pyramidal Cells by Major Interneuron Subtypes in the Auditory Cortex.

Zhong W, Zheng W, Ji X Bioengineering (Basel). 2023; 10(5).

PMID: 37237617 PMC: 10215958. DOI: 10.3390/bioengineering10050547.

VIP-Expressing GABAergic Neurons: Disinhibitory vs. Inhibitory Motif and Its Role in Communication Across Neocortical Areas.

Apicella A, Marchionni I Front Cell Neurosci. 2022; 16:811484.

PMID: 35221922 PMC: 8867699. DOI: 10.3389/fncel.2022.811484.

VIP Modulation of Hippocampal Synaptic Plasticity: A Role for VIP Receptors as Therapeutic Targets in Cognitive Decline and Mesial Temporal Lobe Epilepsy.

Cunha-Reis D, Caulino-Rocha A Front Cell Neurosci. 2020; 14:153.

PMID: 32595454 PMC: 7303298. DOI: 10.3389/fncel.2020.00153.

Characterization of GABAergic marker expression in the chronic unpredictable stress model of depression.

Banasr M, Lepack A, Fee C, Duric V, Maldonado-Aviles J, DiLeone R Chronic Stress (Thousand Oaks). 2017; 1.

PMID: 28835932 PMC: 5565173. DOI: 10.1177/2470547017720459.

References

Borghi C, Nicosia S, Giachetti A, Said S . Vasoactive intestinal polypeptide (VIP) stimulates adenylate cyclase in selected areas of rat brain. Life Sci. 1979; 24(1):65-70. DOI: 10.1016/0024-3205(79)90281-9. View

Petkov V, Kehayov R, Belcheva S, Konstantinova E, Petkov V, Getova D . Memory effects of standardized extracts of Panax ginseng (G115), Ginkgo biloba (GK 501) and their combination Gincosan (PHL-00701). Planta Med. 1993; 59(2):106-14. DOI: 10.1055/s-2006-959623. View

Vaudry D, Gonzalez B, Basille M, Yon L, Fournier A, Vaudry H . Pituitary adenylate cyclase-activating polypeptide and its receptors: from structure to functions. Pharmacol Rev. 2000; 52(2):269-324. View

FLOOD J, Garland J, Morley J . Vasoactive intestinal peptide (VIP): an amnestic neuropeptide. Peptides. 1990; 11(5):933-8. DOI: 10.1016/0196-9781(90)90012-t. View

Kolb B, Sutherland R, Nonneman A, Whishaw I . Asymmetry in the cerebral hemispheres of the rat, mouse, rabbit, and cat: the right hemisphere is larger. Exp Neurol. 1982; 78(2):348-59. DOI: 10.1016/0014-4886(82)90053-x. View

Hozumi S, Nakagawasai O, Tan-No K, Niijima F, Yamadera F, Murata A . Characteristics of changes in cholinergic function and impairment of learning and memory-related behavior induced by olfactory bulbectomy. Behav Brain Res. 2002; 138(1):9-15. DOI: 10.1016/s0166-4328(02)00183-3. View

Takashima A, Maeda Y, Itoh S . Influence of chronic intracerebroventricular infusion of vasoactive intestinal peptide (VIP) on memory processes in Morris water pool test in the rat. Peptides. 1993; 14(5):1073-8. DOI: 10.1016/0196-9781(93)90089-y. View

Moriguchi S, Han F, Nakagawasai O, Tadano T, Fukunaga K . Decreased calcium/calmodulin-dependent protein kinase II and protein kinase C activities mediate impairment of hippocampal long-term potentiation in the olfactory bulbectomized mice. J Neurochem. 2006; 97(1):22-9. DOI: 10.1111/j.1471-4159.2006.03710.x. View

Skelin I, Sato H, Diksic M . Olfactory bulbectomy reduces cerebral glucose utilization: 2-[14C]deoxyglucose autoradiographic study. Brain Res Bull. 2008; 76(5):485-92. DOI: 10.1016/j.brainresbull.2008.01.020. View

10.

Yamaguchi Y, Kobayashi H . Effects of vasoactive intestinal peptide (VIP) on scopolamine-induced amnesia in the rat. Neuropeptides. 1994; 26(3):153-8. DOI: 10.1016/0143-4179(94)90124-4. View

11.

Harmar A, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna J . International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev. 1998; 50(2):265-70. PMC: 6721840. View

12.

Diamond M, Johnson R, Young D, Singh S . Age-related morphologic differences in the rat cerebral cortex and hippocampus: male-female; right-left. Exp Neurol. 1983; 81(1):1-13. DOI: 10.1016/0014-4886(83)90153-x. View

13.

Tadano T, Hozumi S, Yamadera F, Murata A, Niijima F, Tan-No K . Effects of NMDA receptor-related agonists on learning and memory impairment in olfactory bulbectomized mice. Methods Find Exp Clin Pharmacol. 2004; 26(2):93-7. DOI: 10.1358/mf.2004.26.2.800060. View

14.

Brenneman D, Gozes I . A femtomolar-acting neuroprotective peptide. J Clin Invest. 1996; 97(10):2299-307. PMC: 507310. DOI: 10.1172/JCI118672. View

15.

Saiz Ruiz J, Perera J, Hernanz A . [Plasma neuropeptides in affective and anxiety disorders]. Arch Neurobiol (Madr). 1992; 55(1):1-5. View

16.

KRYZHANOVSKII G, Lutsenko V, Karganov M, BELIAEV S . [Lateralization of peptide distribution in the brain and the asymmetry of motor control]. Patol Fiziol Eksp Ter. 1984; (3):68-71. View

17.

Gjerris A . Do concentrations of neurotransmitters in lumbar CSF reflect cerebral dysfunction in depression?. Acta Psychiatr Scand Suppl. 1988; 345:21-4. DOI: 10.1111/j.1600-0447.1988.tb08563.x. View

18.

Masuo Y, Matsumoto Y, Tokito F, Tsuda M, Fujino M . Effects of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) on the spontaneous release of acetylcholine from the rat hippocampus by brain microdialysis. Brain Res. 1993; 611(2):207-15. DOI: 10.1016/0006-8993(93)90504-g. View

19.

Dickson L, Finlayson K . VPAC and PAC receptors: From ligands to function. Pharmacol Ther. 2008; 121(3):294-316. DOI: 10.1016/j.pharmthera.2008.11.006. View

20.

Kruglikov R, Orlova N, Getsova V . Content of norepinephrine and serotonin in symmetrical divisions of the brain of rats in the norm during learning and with the administration of peptides. Neurosci Behav Physiol. 1992; 22(2):128-31. DOI: 10.1007/BF01192384. View